The Filing Desk

bioAffinity Technologies vs OmniAb

bioAffinity Technologies BIAF · OmniAb OABI · Life Sciences Tools & Services

OmniAb reported revenue of $19 million in fiscal 2025, 3.0 times bioAffinity Technologies' $6 million in fiscal 2025. bioAffinity Technologies' revenue fell 34.2% in its latest year, and OmniAb's fell 29.3%. bioAffinity Technologies had an operating margin of -171.6%, against -369.5% at OmniAb. Free cash flow was −$9 million at bioAffinity Technologies and −$37 million at OmniAb.

Side by side

bioAffinity TechnologiesOmniAb
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$19M
Revenue growth−34.2%−29.3%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−171.6%−369.5%
Net margin−242.0%−347.0%
Free cash flow−$9M−$37M
Free cash flow margin−152.4%−198.3%
Return on capital−400.1%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count325.8%11.0%
Last close$1.85$5.03
P/E at the last close——
Insider trades, last 12 monthsbought $1.0 million, sold $1.2 millionsold $283,037
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
bioAffinity TechnologiesOmniAb
Operating margin
Percent of revenue
bioAffinity TechnologiesOmniAb
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
bioAffinity TechnologiesOmniAb

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the bioAffinity Technologies and OmniAb pages.